As the MHRA publishes an update to pharmaceutical companies on preparing for Brexit, the ABPI reaffirms the importance of patient and public health in negotiations.
This week, the Kings Fund published a new report into the cost of medicines looking at how much the health service spends in total on medicines; both generics and branded medicines.
The Medicines and Healthcare products Regulatory Agency (MHRA) has opened a consultation on how its legislation and regulatory processes would have to be modified in the event of the UK not securing a deal with the EU after the UK’s exit, with no Implementation Period.
The ABPI have responded today to an announcement by the Department of Health & Social Care who have published a 12 week consultation seeking views from interested parties on the recommendations in the Cost-Effectiveness Methodology for Immunisation Programmes and Procurement (CEMIPP).
The ABPI has responded to the Prime Minister's ‘Road to Brexit’ speech today at Mansion House.
On Wednesday 21 February, Health and Social Care Secretary Jeremy Hunt announced that Baroness Julia Cumberlege will lead a review into how the NHS responds to safety concerns raised by patients about medicines or medical devices.
This morning, The Times published an investigation into the transfers of value received by healthcare professionals (HCPs) and healthcare organisations (HCOs) across Europe from the pharmaceutical industry.
The Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise Oxford University/AstraZeneca’s Covid-19 vaccine for use.
The first vaccine for COVID-19 has been approved for use by the UK's independent regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA) today.
The ABPI welcomes the publication of today's consultation on NICE's Methods and the launched of a public consultation on proposals for changes to the methods it uses to develop its guidance on medicines, medical devices and diagnostics.